Temoporfin

Drug Profile

Temoporfin

Alternative Names: EF 9; Foscan; KW 2345; m-THPC; meta-Tetrahydroxyphenyl chlorin

Latest Information Update: 15 Feb 2016

Price : $50

At a glance

  • Originator QuantaNova
  • Developer biolitec; University of Salzburg
  • Class Antineoplastics; Mesoporphyrins
  • Mechanism of Action Photosensitisers; Reactive oxygen species stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Head and neck cancer
  • Phase II Basal cell cancer; Cholangiocarcinoma; Lipoma; Prostate cancer

Most Recent Events

  • 01 Oct 2008 Kirin Pharma Company has merged with Kyowa Hakko to form Kyowa Hakko Kirin
  • 17 Mar 2003 A study has been added to the Cancer therapeutic trials section
  • 07 Mar 2002 Suspended - Preregistration for Head and neck cancer in USA (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top